Baran KW August 28, 2000 Kenneth W. Baran MD for the LIMIT AMI Investigators St. Paul Heart Clinic, St. Paul, MN, USA Sponsor: Genentech Inc., South San.

Slides:



Advertisements
Similar presentations
GUSTO-IV AMI G lobal U se of S trategies T o Open O ccluded Coronary Arteries in AMI.
Advertisements

Intracoronary Autologous Bone-Marrow Cell Transfer after Myocardial Infarction: A Double-Blind, Randomized, and Placebo-Controlled Clinical Trial Presented.
Relationship of Time to Treatment and Door-to-Balloon Time to Mortality in Patients with Acute Myocardial Infarction Treated with Primary Angioplasty Christopher.
Management of Acute Myocardial Infarction Minimal Acceptable vs Optimal Care Hussien H. Rizk, MD Cairo University.
Comparison of AngioJET Rheolytic Thrombectomy Before Direct Infarct Artery STENTing in Patients with Acute Myocardial Infarction: the JETSTENT trial David.
Comparison of AngioJET Rheolytic Thrombectomy Before Direct Infarct Artery STENTing in Patients with Acute Myocardial Infarction: the JETSTENT trial David.
Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.
Randomized Angioplasty Beta Blocker Intracoronary Trial II (RABBIT II) Presented at The American Heart Association Scientific Session 2006 Presented by.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 53 Management of ST-Elevation Myocardial Infarction.
The AiMI Trial Arshad Ali, MD, David Cox, MD, Nabil Dib, MD, Bruce Brodie, MD, Daniel Berman, MD, Navin Gupta, MD, Kevin Browne, MD, Robert Iwaoka, MD,
Download from Slide 1 AGGRASTAT ® † (tirofiban, MSD) to ZOCOR ™ † (simvastatin, MSD) (A to Z) Trial Results from the AGGRASTAT.
Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.
Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction Results of the Antithrombotics.
Slide 1 AGGRASTAT ™ † (tirofiban, MSD) to ZOCOR ™ † (simvastatin, MSD) (A to Z) Trial Results from the AGGRASTAT Phase † Trademarks of Merck & Co., Inc.,
Intravenous GP IIb/IIIa Inhibitors Abciximab (c7E3 Fab, ReoPro) = Human- murine chimeric monoclonal Fab antibody fragment Eptifibatide (Integrilin) =
Effects of PG , a Matrix Metalloproteinase Inhibitor to Prevent Left Ventricular Remodeling After Acute Myocardial Infarction Effects of PG ,
TIMI 11A A Multicenter Trial of the Safety and Tolerability of Two Doses of Enoxaparin in Patients With Unstable Angina and Non-Q-Wave Myocardial Infarction.
Enhancement of thrombolysis in AMI is an unmet clinical need Increase the rate of reperfusion without increasing bleeding Reduce the time to complete reperfusion.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
The ASSENT 3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT 3 randomised.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
TREATMENT OF ACUTE MYOCARDIAL INFARCTION NUR 351/352 PROFESSOR DIANE E. WHITE RN MS CCRN.
Which Early ST-Elevation Myocardial Infarction Therapy (WEST) Trial Paul W. Armstrong, WEST Steering Committee Published in The European Heart Journal.
Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.
Baseline Characteristics Current or Former Smoker Diabetic Hypertension 25.7 Prior MI Prior Heart Failure.
Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial Presented at AHA Scientific Sessions Nov. 15, 2000.
Rescue Angioplasty versus Conservative Therapy or Repeat Thrombolysis Trial Presented at American Heart Association Scientific Sessions 2004 Presented.
Safety and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention: an International Randomized Evaluation (STEEPLE) Presented.
The INT egrelin and E noxaparin R andomized assessment of A cute C oronary syndrome Treatment T rial Sponsored by the Canadian Heart Research Centre, Key.
RP Giugliano MD, SM; MT Roe, MD, MHS; RA Harrington MD; CM Gibson, MS, MD; U Zeymer, MD; F Van de Werf, MD, PhD; KW Baran, MD; HP Hobbach, MD; LH Woodlief,
The 90 Minute Wall: 60% Rates of TIMI Grade 3 Flow % TIMI 3 Flow.
The Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented.
A Prospective, Randomized Evaluation of Supersaturated Oxygen Therapy After Percutaneous Coronary Intervention in Acute Anterior Myocardial Infarction.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
GUSTO IV ACS: Trial Design Abciximab versus placebo in very high-risk patients with non-ST elevation acute coronary syndromes: – ST  > 0.5 mm or – elevated.
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
Trial Vignettes 1-3 Mark Mason Harefield Hospital Royal Brompton and Harefield NHS Trust.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
NICE-3 National Investigators Collaborating on Enoxaparin XXII nd Congress of the European Society of Cardiology August 30, 2000 Amsterdam, The Netherlands.
AntiThrombotic Therapy in the Cath Lab: Preliminary Results from the NICE Trials Cindy L. Grines, M.D. William Beaumont Hospital Royal Oak, Michigan Cindy.
Impact Of Diabetes Mellitus On The Safety And Effectiveness Of Bivalirudin In Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty:
Randomized Early versus Late AbciXimab in Acute Myocardial Infarction treated with primary coronary intervention (RELAx-AMI Trial) Mauro Maioli M.D., Francesco.
SPEED : GUSTO-IV PILOT GUSTO-IV Pilot Trial. SPEED : GUSTO-IV PILOT Rationale for Combination Therapy in AMI Enhance Incidence and Speed of Reperfusion.
Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented at.
Rationale for the Clinical Evaluation of Combination GP IIb-IIIa Inhibitor and Low-Dose Fibrinolytic Therapy in ST-Elevation Myocardial Infarction.
1 Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial N Engl J Med 2001;344:
Total Occlusion Study of Canada (TOSCA-2) Trial
Dartmouth Hitchcock Medical Center
The American College of Cardiology Presented by Dr. Adnan Kastrati
Management of ST-Elevation Myocardial Infarction
The European Society of Cardiology Presented by Dr. Saman Rasoul
Study Design AMI <12 hours, any age, cardiogenic shock excluded
Presented by Dr. Leif Thuesen
Dabigatran in myocardial injury after noncardiac surgery
European Society of Cardiology 2003
GUSTO-IV ACS GUSTO IV ACS evaluated the safety and efficacy of abciximab given as first line medical therapy in a broad population of patients with non-ST.
The following slides are based on a presentation at a Satellite Symposium in association with the Annual Cardiovascular Conference at Lake Louise, Alberta,
Becker RC, et al. Lancet 2009;373:919-28
Published in the European Heart Journal
TIMI IIIA Protocol Design 391 Patients with Unstable Angina / NQWMI
American Heart Association Presented by Dr. Julinda Mehilli
Erasmus MC, Thoraxcenter
Secondary Efficacy Endpoints
Maintenance of Long-Term Clinical Benefit with
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Update on the New Antiplatelet Agents:
European Heart Journal Advance Access
INTRO AMI. INTEGRILIN AND. REDUCED DOSE. OF THROMBOLYTIC IN. ACUTE
Presentation transcript:

Baran KW August 28, 2000 Kenneth W. Baran MD for the LIMIT AMI Investigators St. Paul Heart Clinic, St. Paul, MN, USA Sponsor: Genentech Inc., South San Francisco, USA LIMIT AMI (LImitation of Myocardial Injury following Thrombolysis in Acute Myocardial Infarction) An angiographic safety and efficacy trial of a novel anti-CD18 therapy in acute myocardial infarction in conjunction with thrombolysis

Baran KW August 28, 2000

rhuMAb CD18 â Antibody fragment [F(ab’) 2 ] â Single dose administered as IV bolus â Plasma half-life 7 to 10 hours â  90% CD18-containing receptor saturation maintained for ~ 24 hours (0.5 mg/kg) and ~ 48 hours (2.0 mg/kg)

Baran KW August 28, 2000 The LIMIT AMI Trial of rhuMAb CD18 ST elevation > 2 leads Symptoms < 12 hrs No prior coronary surgery No cardiogenic shock No thrombolytic exclusions No major immune-related risks ScreeningScreening

Baran KW August 28, 2000 The LIMIT AMI Trial of rhuMAb CD18 ST elevation > 2 leads Symptoms < 12 hrs No prior coronary surgery No cardiogenic shock No thrombolytic exclusions No major immune-related risks ScreeningScreening Randomization 1:1:1 with administration prior to full-dose tPA 2 mg/kg0.5 mg/kg Placebo + usual care including aspirin, IV heparin

Baran KW August 28, 2000 The LIMIT AMI Trial of rhuMAb CD18 ST elevation > 2 leads Symptoms < 12 hrs No prior coronary surgery No cardiogenic shock No thrombolytic exclusions No major immune-related risks ScreeningScreening Coronary angiography 90 minutes from tPA initiation Randomization 1:1:1 to study drug or placebo then full-dose tPA 2 mg/kg0.5 mg/kg Placebo Corrected TIMI Frame Count, TIMI Flow Grade TIMI Myocardial Perfusion Grade Angioplasty ± Gp IIb/IIIa inhibitors as required + usual care including aspirin, IV heparin

Baran KW August 28, 2000 The LIMIT AMI Trial of rhuMAb CD18 Infarct size sestamibi at rest, day 6-9 CKMB 0-72 hours ECG ST segment resolution 180 minutes Fever Antibiotic use General Safety Other endpoints

Baran KW August 28, 2000 Statistical Analysis â Efficacy endpoint data analyzed by independent and blinded Core Laboratories â Time windows were used for efficacy endpoints using imputation for missing data where possible â “As treated” analysis of the evaluable cohort â Sensitivity analyses â p values: non parametric tests

Baran KW August 28, 2000 Results â Enrollment from September 1998 to March 2000 â 413 subjects randomized â 394 treated with rhuMAb CD18 or placebo â 19 randomized but not treated Ý mainly due to review of exclusion criteria â 60 centers in US and Canada

Baran KW August 28, 2000 Baseline characteristics

Baran KW August 28, 2000 Concomitant Interventions

Baran KW August 28, 2000 Change in peripheral venous blood white cell counts - mean values

Baran KW August 28, 2000 Primary Endpoint: Corrected TIMI Frame minutes Corrected TIMI Frame Count Placebo0.5 mg/kg2.0 mg/kg Treatment Received p = 0.2 p = 1.0meanmedian

Baran KW August 28, 2000 % TIMI Grade 3 flow Expected per protocol: placebo 55%, treatment 70% N=114 N=111N=108 66% 58% 63%

Baran KW August 28, 2000 TIMI Flow Grades (all grades) N=114 N=111 N=108

Baran KW August 28, 2000 TIMI Myocardial Perfusion Grade N=107 N=101 N=102

Baran KW August 28, 2000 ECG ST segment elevation resolution at 180 minutes N=109 N=103 N=106

Baran KW August 28, 2000 Infarct Size by sestamibi scan Day 6-9 LV defect % Placebo 0.5 mg/kg 2.0 mg/kg Treatment Receivedmeanmedian

Baran KW August 28, 2000 Clinical outcomes at Day 30 * Adverse Event report, complications CRF, or readmission diagnosis ** CHF Killip III or IV, or CHF readmission, or CHF Adverse Event (serious or severe or cardiogenic shock) *** Death, CHF or recurrent AMI

Baran KW August 28, 2000 Safety - fever and antibiotic use N=129 N=131 N=134

Baran KW August 28, 2000 Safety - Likely bacterial infections N=134 N=129 N=131 95% CI

Baran KW August 28, 2000 General Safety â No effect on fibrinogen or d-dimer levels â No increase in “serious and life-threatening bleeding” â Slight trend towards increases in overall bleeding adverse events (  10%) and transfusions (  20%) â Small number of mild thrombocytopenia cases < 100,000/mm 3 : placebo 2 cases, 0.5 mg/kg 1 case, 2.0 mg/kg 5 cases â No specific anti-rhuMAb CD18 antibody formation* * Except for one 30 Day sample with possible low level anti-CDR activity still under investigation.

Baran KW August 28, 2000 Conclusions ârhuMAb CD18, in conjunction with thrombolysis, had no effect on coronary flow, infarct size or ECG ST segment resolution âThese results are consistent with the findings of another Phase II study of an anti-CD18 antibody in Primary Angioplasty on infarct size (HALT MI*) âThere may be non CD18- dependent leukocyte binding and transmigration in AMI âLeukocytes may not be key to ischemia- reperfusion injury in human AMI * Faxon D, Annual Meeting of the American Heart Association, Atlanta, November 1999